Join founder and executive director of MAPS, Rick Doblin, Ph.D., for an update on the approval of MDMA-assisted psychotherapy as a treatment for PTSD. MAPS is on a mission to secure FDA approval for MDMA-assisted psychotherapy as a prescribed medication, with the federal agency labelling it a ‘breakthrough therapy’. Rick will discuss the treatment’s successes to date, regulation once ratified and its wider applications – such as in the treatment of eating disorders.
Date: Tuesday, June 30th
Time: 3:00 PM – 4:30 PM PST (6:00 PM – 7:30 PM EST)
About Rick Doblin, Ph.D
Rick Doblin’s passion and positivity is infectious, which makes him a catalyst for change in the psychedelic renaissance. A visionary and stalwart in the use of psychedelics to treat mental illness, Rick founded MAPS to study their beneficial application in 1986.
Rick attended Harvard’s prestigious Kennedy School of Government, where he received his doctorate in Public Policy in 1982. At a time when entheogen research was repressed, Rick wrote his doctorate promoting the regulation of psychedelics, in addition to a thesis on cannabis use in cancer patients.
As a continuation of his studies, Rick completed a psychology degree at New College of Florida – with a continuation of the Marsh Chapel Experiment, or Good Friday Experiment, which explored the potential of psychedelics to produce religious experiences. In addition to this 25-year-follow-up, he also replicated Timothy Leary’s classic Concord Prison Experiment to investigate the efficacy of psilocybin-assisted psychotherapy in criminal rehabilitation.
By conducting seminal psychedelic experiments decades later, Rick rekindled a renaissance in entheogen research that continues to this day. Thirty years after he founded MAPS in response to the DEA’s inaccurate scheduling of MDMA, the organization has contributed over $20 million USD to identify therapeutic applications for psychedelics. Fittingly, MAPS’ current top priority is to develop MDMA-assisted psychotherapy into an approved FDA treatment for PTSD – which the federal agency labelled a ‘breakthrough therapy’.
It’s this exciting development that Rick will discuss in the next instalment of Examining the Psychedelic Renaissance. Rick will provide an update on the therapy’s progression through the Phase 3 drug development process, ongoing research and MAPS’s latest sponsored study on MDMA-assisted psychotherapy for eating disorders.
You can read more about Rick here.
MAPS Canada has priced the Examining the Psychedelic Renaissance webinar series at an affordable $111 for the full 14 episodes. Single episodes are available for $22 each, with discounted rates for students, seniors and those affected by COVID-19. Tickets can be purchased online at www.mapscanada.org/webinar